Encompass boosts 2026 guidance, raises buyback authorization
Encompass Health reported robust Q2 2026 results and raised its full-year guidance for net operating revenue and adjusted earnings, alongside increasing its common stock repurchase authorization to $1 billion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day